II. Definitions
- Ascending Cholangitis
- Acute, life threatening infection of the biliary tree by Bacteria ascending from the Small Intestine (duodenum)
- Associated with bile duct obstruction (e.g. Common Bile Duct Stone) resulting in hepatic intraductal pressure increase
III. Epidemiology
-
Incidence rare under age 40 years
- However can occur in children with risk factors
IV. Risk Factors
- Choledocolithiasis
- Biliary atresia or Biliary tract stricture
- Surgical anastomotic stricture
- Extrinsic compression from malignancy
- Liver Transplant history
- Roux-en-Y Bypass Surgery
V. Pathophysiology
- Complete biliary duct obstruction (Choledocolithiasis)
- Results in increased hepatic intraductal pressures
- Intestinal Bacteria (Gram Negative Bacteria, Anaerobic Bacteria) pass through sphincter of odi from duodenum
- E. coli (25-50%)
- Klebsiella (15-20%)
- Enterobacter (5-10%)
- Enterococcus (10-20%)
- Bacteroides
- Clostridium
- Pseudomonas
- Reflux of Bacteria into the Lymphatics, hepatitic veins
- Results in systemic spread and rapid progression to Sepsis
VI. Symptoms
VII. Signs
- Presentations may be cryptic
- Altered Mental Status
- Sepsis with unknown source
- Charcot's Triad (Test Sensitivity 25%, Test Specificity 85%)
- Reynold's Pentad (7 to14% of patients)
- Charcot's Triad and
- Hypotension (Shock) and
- Altered Mental Status
- Other findings
- Fever (>40% of patients)
- Abdominal Pain (>60% of patients)
- Jaundice (60 to 70% of patients)
- Toxic appearance
- Hepatomegaly (with tender liver edge)
- Splenomegaly
VIII. Labs
-
Complete Blood Count
-
Leukocytosis (>80% of patients)
- Leukopenia (<4000/mm3) may be present instead
- Neutrophil to Lymphocyte ratio (NLR) >5.3
-
Leukocytosis (>80% of patients)
-
Liver Function Tests abnormal
- Total Bilirubin elevated in urine and plasma (40% of patients)
- Greater Test Specificity for Cholangitis when Total Bilirubin >4 mg/dl
- Serum alkaline phsophatase elevated (>90% of patients)
- Gamma glutamyl transferase elevated (>90% of patients)
- Transaminases (AST, ALT) may also be increased
- Total Bilirubin elevated in urine and plasma (40% of patients)
-
Blood Cultures (positive in 50 to 70% of patients)
- Gram Negative bacteremia
IX. Imaging
-
RUQ Ultrasound
- Dilated common bile duct (>7 mm, or post-Cholecystectomy >10 mm)
- Dilated intrahepatic ducts
- Test Sensitivity 25-60% for Common Bile Duct Stones
- Do not rely on RUQ Ultrasound to exclude Ascending Cholangitis when suspicion is high
- Consider serial Ultrasounds and advanced imaging
-
CT Abdomen and Pelvis with IV Contrast
- Dilated and obstructed common bile ducts and intrahepatic ducts (including external compression forces)
- Preferred study in evaluating cause and complications from Cholangitis
- MRI Abdomen with MRCP
- Indicated when CT and Ultrasound are non-diagnostic
X. Differential Diagnosis
- See Sepsis
- Acute Cholecystitis
- Post-op status (esp. Laparoscopic Cholecystectomy) Bile Duct Injury with Biliary Leak
- Acute Pancreatitis
- Liver Abscess
XI. Grading (Tokyo Guidelines 13)
- Severe (1 or more criteria)
- Hypotension requiring Vasopressors
- Altered Mental Status
- PaO2/FIO2 <300
- Oliguria
- Serum Creatinine >2 mg/dl
- INR >1.5
- Platelet Count <100,000/mm3
- Moderate (2 or more criteria)
- White Blood Cell Count >12,000 or <4000/mm3
- Fever >=39 C (102.2 F)
- Age >= 75 years old
- Total Bilirubin >= 5 mg/dl
- Albumin <70% of lower limit of normal
- Mild
- Criteria not sufficient for moderate or severe Cholangitis
XII. Management
- See Acute Cholecystitis
- See Cholecystectomy
- Broad spectrum ParenteralAntibiotics (Gram Negatives, enteric Streptococcus, Anaerobes)
- Initial Antibiotic regimen for life threatening infection
- Piperacillin-Tazobactam 4.5 g IV q8 hours OR
- Ertapenem 1 g IV every 24 hours OR
- Other Carbapenems
- Alternative Antibiotic regimen (2 drug regimen)
- Metronidazole 1 g IV load, then 500 mg IV every 6 hours AND
- Cefepime or Ceftazidime
- Initial Antibiotic regimen for mild to moderate community acquired infection
- Metronidazole 500 mg IV every 6 hours AND
- One of the following
- Cephalosporin (Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime) OR
- Fluoroquinolone (Moxifloxacin 400 IV q24h or Ciprofloxacin 400 mg IV q12 h)
- Risk of Fluoroquinolone resistance
- Additional Antibiotics if indicated
- Vancomycin
- May be added to regimen if Healthcare Associated Infection
- Vancomycin
- References
- (2019) Acute Cholangitis, Sanford Guide, accessed 3/29/2019
- (2019) Acute Cholangitis, UpToDate, accessed 3/29/2019
- Initial Antibiotic regimen for life threatening infection
-
Sepsis and symptomatic management
- See Septic Shock
- Volume Resuscitation with IV fluids
- Vasopressor support as needed
- Opioid Analgesics
- Endotracheal Intubation is often required in severe cases
- Rapid decompression of biliary tree
- Endoscopy with ERCP and sphincterotomy
- Preferred as initial intervention (90% success rate)
- Emergent ERCP decompression in severe cases
- Mild to moderate Cholangitis responds well to Antibiotics in 70-80% of patients
- ERCP decompression may be delayed 24-48 hours in these cases
- Urgent ERCP decompression is indicated if poor response to Antibiotics in first 24 hours
- Delayed ERCP >48 hours when medical management has failed is associated with worse outcomes
- Prolonged hospitalization, ICU stay, Ventilator support, Vasopressor support and organ failure
- Increased mortality as high as 80%
- Percutaneous drainage of biliary tree
- Consider when ERCP not possible (e.g. Roux-en-Y Bypass, whipple resection, duodenal stenosis)
- Open common bile duct exploration
- High mortality and morbidity
- Consider in cases refractory to other measures
- Endoscopy with ERCP and sphincterotomy
XIII. Prognosis
- Mortality approaches 100% if untreated
- High mortality (up to 30%) even with optimal care
XIV. References
- Long and Swaminathan in Swadron (2022) EM:Rap 22(11): 16-21
- Abraham (2014) Am Fam Physician 89(10): 795-802 [PubMed]
- Poon (2001) Arch Surg 136:11-6 [PubMed]
- Portincasa (2006) Lancet 368(9531):230-9 [PubMed]